Comparative Pharmacology
Head-to-head clinical analysis: CARBATROL versus DEPAKOTE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBATROL versus DEPAKOTE ER.
CARBATROL vs DEPAKOTE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-gated sodium channels, inhibiting repetitive firing of action potentials. Also enhances GABAergic activity.
Increases GABAergic activity by inhibiting GABA transaminase and succinate semialdehyde dehydrogenase; blocks voltage-gated sodium and T-type calcium channels; reduces glutamate release.
Initial dose 200 mg orally twice daily, increase by 200 mg/day at weekly intervals; maintenance 800-1200 mg/day in 2 divided doses extended-release capsules.
500-1000 mg orally once daily; usual maximum dose 60 mg/kg/day.
None Documented
None Documented
Terminal elimination half-life 25-65 hours initially, then 12-17 hours after autoinduction; clinical context: requires dose adjustment after 3-5 weeks.
Terminal elimination half-life is approximately 20 hours (range 10-60 hours); clinical context: extended-release formulation allows once-daily dosing, steady-state achieved in 4-5 days
Renal: 70% as metabolites (including carbamazepine-10,11-epoxide) and 2-3% as unchanged drug; biliary/fecal: 30%.
Primarily renal (30-50% as glucuronide conjugates, <3% as unchanged drug); minor fecal (10-20%)
Category C
Category C
Anticonvulsant
Anticonvulsant